Detailed TOC of Global CD30 (TNFRSF8) Antibody Market Research Report 2025
1 CD30 (TNFRSF8) Antibody Market Overview
1.1 Product Overview and Scope of CD30 (TNFRSF8) Antibody
1.2 CD30 (TNFRSF8) Antibody Segment by Type
1.2.1 Global CD30 (TNFRSF8) Antibody Market Value Comparison by Type (2025-2033)
1.2.2 Monoclonal Antibody
1.2.3 Polyclonal Antibody
1.3 CD30 (TNFRSF8) Antibody Segment by Application
1.3.1 Global CD30 (TNFRSF8) Antibody Market Value by Application: (2025-2033)
1.3.2 Flow Cytometry
1.3.3 ELISA
1.3.4 Western Blot
1.3.5 Immunofluorescence
1.3.6 Others
1.4 Global CD30 (TNFRSF8) Antibody Market Size Estimates and Forecasts
1.4.1 Global CD30 (TNFRSF8) Antibody Revenue 2018-2033
1.4.2 Global CD30 (TNFRSF8) Antibody Sales 2018-2033
1.4.3 Global CD30 (TNFRSF8) Antibody Market Average Price (2018-2033)
1.5 Assumptions and Limitations
2 CD30 (TNFRSF8) Antibody Market Competition by Manufacturers
2.1 Global CD30 (TNFRSF8) Antibody Sales Market Share by Manufacturers (2018-2025)
2.2 Global CD30 (TNFRSF8) Antibody Revenue Market Share by Manufacturers (2018-2025)
2.3 Global CD30 (TNFRSF8) Antibody Average Price by Manufacturers (2018-2025)
2.4 Global CD30 (TNFRSF8) Antibody Industry Ranking 2021 VS 2022 VS 2025
2.5 Global Key Manufacturers of CD30 (TNFRSF8) Antibody, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of CD30 (TNFRSF8) Antibody, Product Type & Application
2.7 CD30 (TNFRSF8) Antibody Market Competitive Situation and Trends
2.7.1 CD30 (TNFRSF8) Antibody Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest CD30 (TNFRSF8) Antibody Players Market Share by Revenue
2.7.3 Global CD30 (TNFRSF8) Antibody Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 CD30 (TNFRSF8) Antibody Retrospective Market Scenario by Region
3.1 Global CD30 (TNFRSF8) Antibody Market Size by Region: 2018 Versus 2022 Versus 2033
3.2 Global CD30 (TNFRSF8) Antibody Global CD30 (TNFRSF8) Antibody Sales by Region: 2018-2033
3.2.1 Global CD30 (TNFRSF8) Antibody Sales by Region: 2018-2025
3.2.2 Global CD30 (TNFRSF8) Antibody Sales by Region: 2025-2033
3.3 Global CD30 (TNFRSF8) Antibody Global CD30 (TNFRSF8) Antibody Revenue by Region: 2018-2033
3.3.1 Global CD30 (TNFRSF8) Antibody Revenue by Region: 2018-2025
3.3.2 Global CD30 (TNFRSF8) Antibody Revenue by Region: 2025-2033
3.4 North America CD30 (TNFRSF8) Antibody Market Facts & Figures by Country
3.4.1 North America CD30 (TNFRSF8) Antibody Market Size by Country: 2018 VS 2022 VS 2033
3.4.2 North America CD30 (TNFRSF8) Antibody Sales by Country (2018-2033)
3.4.3 North America CD30 (TNFRSF8) Antibody Revenue by Country (2018-2033)
3.4.4 United States
3.4.5 Canada
3.5 Europe CD30 (TNFRSF8) Antibody Market Facts & Figures by Country
3.5.1 Europe CD30 (TNFRSF8) Antibody Market Size by Country: 2018 VS 2022 VS 2033
3.5.2 Europe CD30 (TNFRSF8) Antibody Sales by Country (2018-2033)
3.5.3 Europe CD30 (TNFRSF8) Antibody Revenue by Country (2018-2033)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific CD30 (TNFRSF8) Antibody Market Facts & Figures by Country
3.6.1 Asia Pacific CD30 (TNFRSF8) Antibody Market Size by Country: 2018 VS 2022 VS 2033
3.6.2 Asia Pacific CD30 (TNFRSF8) Antibody Sales by Country (2018-2033)
3.6.3 Asia Pacific CD30 (TNFRSF8) Antibody Revenue by Country (2018-2033)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America CD30 (TNFRSF8) Antibody Market Facts & Figures by Country
3.7.1 Latin America CD30 (TNFRSF8) Antibody Market Size by Country: 2018 VS 2022 VS 2033
3.7.2 Latin America CD30 (TNFRSF8) Antibody Sales by Country (2018-2033)
3.7.3 Latin America CD30 (TNFRSF8) Antibody Revenue by Country (2018-2033)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa CD30 (TNFRSF8) Antibody Market Facts & Figures by Country
3.8.1 Middle East and Africa CD30 (TNFRSF8) Antibody Market Size by Country: 2018 VS 2022 VS 2033
3.8.2 Middle East and Africa CD30 (TNFRSF8) Antibody Sales by Country (2018-2033)
3.8.3 Middle East and Africa CD30 (TNFRSF8) Antibody Revenue by Country (2018-2033)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global CD30 (TNFRSF8) Antibody Sales by Type (2018-2033)
4.1.1 Global CD30 (TNFRSF8) Antibody Sales by Type (2018-2025)
4.1.2 Global CD30 (TNFRSF8) Antibody Sales by Type (2025-2033)
4.1.3 Global CD30 (TNFRSF8) Antibody Sales Market Share by Type (2018-2033)
4.2 Global CD30 (TNFRSF8) Antibody Revenue by Type (2018-2033)
4.2.1 Global CD30 (TNFRSF8) Antibody Revenue by Type (2018-2025)
4.2.2 Global CD30 (TNFRSF8) Antibody Revenue by Type (2025-2033)
4.2.3 Global CD30 (TNFRSF8) Antibody Revenue Market Share by Type (2018-2033)
4.3 Global CD30 (TNFRSF8) Antibody Price by Type (2018-2033)
5 Segment by Application
5.1 Global CD30 (TNFRSF8) Antibody Sales by Application (2018-2033)
5.1.1 Global CD30 (TNFRSF8) Antibody Sales by Application (2018-2025)
5.1.2 Global CD30 (TNFRSF8) Antibody Sales by Application (2025-2033)
5.1.3 Global CD30 (TNFRSF8) Antibody Sales Market Share by Application (2018-2033)
5.2 Global CD30 (TNFRSF8) Antibody Revenue by Application (2018-2033)
5.2.1 Global CD30 (TNFRSF8) Antibody Revenue by Application (2018-2025)
5.2.2 Global CD30 (TNFRSF8) Antibody Revenue by Application (2025-2033)
5.2.3 Global CD30 (TNFRSF8) Antibody Revenue Market Share by Application (2018-2033)
5.3 Global CD30 (TNFRSF8) Antibody Price by Application (2018-2033)
6 Key Companies Profiled
6.1 Sino Biological, Inc.
6.1.1 Sino Biological, Inc. Corporation Information
6.1.2 Sino Biological, Inc. Description and Business Overview
6.1.3 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Sales, Revenue and Gross Margin (2018-2025)
6.1.4 Sino Biological, Inc. CD30 (TNFRSF8) Antibody Product Portfolio
6.1.5 Sino Biological, Inc. Recent Developments/Updates
6.2 Bio-Techne
6.2.1 Bio-Techne Corporation Information
6.2.2 Bio-Techne Description and Business Overview
6.2.3 Bio-Techne CD30 (TNFRSF8) Antibody Sales, Revenue and Gross Margin (2018-2025)
6.2.4 Bio-Techne CD30 (TNFRSF8) Antibody Product Portfolio
6.2.5 Bio-Techne Recent Developments/Updates
6.3 Thermo Fisher Scientific (China) Co., Ltd.
6.3.1 Thermo Fisher Scientific (China) Co., Ltd. Corporation Information
6.3.2 Thermo Fisher Scientific (China) Co., Ltd. Description and Business Overview
6.3.3 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Sales, Revenue and Gross Margin (2018-2025)
6.3.4 Thermo Fisher Scientific (China) Co., Ltd. CD30 (TNFRSF8) Antibody Product Portfolio
6.3.5 Thermo Fisher Scientific (China) Co., Ltd. Recent Developments/Updates
6.4 Boster Biological Technology
6.4.1 Boster Biological Technology Corporation Information
6.4.2 Boster Biological Technology Description and Business Overview
6.4.3 Boster Biological Technology CD30 (TNFRSF8) Antibody Sales, Revenue and Gross Margin (2018-2025)
6.4.4 Boster Biological Technology CD30 (TNFRSF8) Antibody Product Portfolio
6.4.5 Boster Biological Technology Recent Developments/Updates
6.5 MyBiosource, Inc.
6.5.1 MyBiosource, Inc. Corporation Information
6.5.2 MyBiosource, Inc. Description and Business Overview
6.5.3 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Sales, Revenue and Gross Margin (2018-2025)
6.5.4 MyBiosource, Inc. CD30 (TNFRSF8) Antibody Product Portfolio
6.5.5 MyBiosource, Inc. Recent Developments/Updates
6.6 Abeomics Inc.
6.6.1 Abeomics Inc. Corporation Information
6.6.2 Abeomics Inc. Description and Business Overview
6.6.3 Abeomics Inc. CD30 (TNFRSF8) Antibody Sales, Revenue and Gross Margin (2018-2025)
6.6.4 Abeomics Inc. CD30 (TNFRSF8) Antibody Product Portfolio
6.6.5 Abeomics Inc. Recent Developments/Updates
6.7 Abbexa
6.6.1 Abbexa Corporation Information
6.6.2 Abbexa Description and Business Overview
6.6.3 Abbexa CD30 (TNFRSF8) Antibody Sales, Revenue and Gross Margin (2018-2025)
6.4.4 Abbexa CD30 (TNFRSF8) Antibody Product Portfolio
6.7.5 Abbexa Recent Developments/Updates
6.8 Cell Signaling Technology, Inc.
6.8.1 Cell Signaling Technology, Inc. Corporation Information
6.8.2 Cell Signaling Technology, Inc. Description and Business Overview
6.8.3 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Sales, Revenue and Gross Margin (2018-2025)
6.8.4 Cell Signaling Technology, Inc. CD30 (TNFRSF8) Antibody Product Portfolio
6.8.5 Cell Signaling Technology, Inc. Recent Developments/Updates
6.9 Creative Diagnostics
6.9.1 Creative Diagnostics Corporation Information
6.9.2 Creative Diagnostics Description and Business Overview
6.9.3 Creative Diagnostics CD30 (TNFRSF8) Antibody Sales, Revenue and Gross Margin (2018-2025)
6.9.4 Creative Diagnostics CD30 (TNFRSF8) Antibody Product Portfolio
6.9.5 Creative Diagnostics Recent Developments/Updates
6.10 OriGene Technologies, Inc.
6.10.1 OriGene Technologies, Inc. Corporation Information
6.10.2 OriGene Technologies, Inc. Description and Business Overview
6.10.3 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Sales, Revenue and Gross Margin (2018-2025)
6.10.4 OriGene Technologies, Inc. CD30 (TNFRSF8) Antibody Product Portfolio
6.10.5 OriGene Technologies, Inc. Recent Developments/Updates
6.11 Merck
6.11.1 Merck Corporation Information
6.11.2 Merck CD30 (TNFRSF8) Antibody Description and Business Overview
6.11.3 Merck CD30 (TNFRSF8) Antibody Sales, Revenue and Gross Margin (2018-2025)
6.11.4 Merck CD30 (TNFRSF8) Antibody Product Portfolio
6.11.5 Merck Recent Developments/Updates
6.12 Cayman Chemical
6.12.1 Cayman Chemical Corporation Information
6.12.2 Cayman Chemical CD30 (TNFRSF8) Antibody Description and Business Overview
6.12.3 Cayman Chemical CD30 (TNFRSF8) Antibody Sales, Revenue and Gross Margin (2018-2025)
6.12.4 Cayman Chemical CD30 (TNFRSF8) Antibody Product Portfolio
6.12.5 Cayman Chemical Recent Developments/Updates
6.13 CUSABIO
6.13.1 CUSABIO Corporation Information
6.13.2 CUSABIO CD30 (TNFRSF8) Antibody Description and Business Overview
6.13.3 CUSABIO CD30 (TNFRSF8) Antibody Sales, Revenue and Gross Margin (2018-2025)
6.13.4 CUSABIO CD30 (TNFRSF8) Antibody Product Portfolio
6.13.5 CUSABIO Recent Developments/Updates
6.14 Biotium
6.14.1 Biotium Corporation Information
6.14.2 Biotium CD30 (TNFRSF8) Antibody Description and Business Overview
6.14.3 Biotium CD30 (TNFRSF8) Antibody Sales, Revenue and Gross Margin (2018-2025)
6.14.4 Biotium CD30 (TNFRSF8) Antibody Product Portfolio
6.14.5 Biotium Recent Developments/Updates
6.15 BioLegend
6.15.1 BioLegend Corporation Information
6.15.2 BioLegend CD30 (TNFRSF8) Antibody Description and Business Overview
6.15.3 BioLegend CD30 (TNFRSF8) Antibody Sales, Revenue and Gross Margin (2018-2025)
6.15.4 BioLegend CD30 (TNFRSF8) Antibody Product Portfolio
6.15.5 BioLegend Recent Developments/Updates
6.16 Abcepta
6.16.1 Abcepta Corporation Information
6.16.2 Abcepta CD30 (TNFRSF8) Antibody Description and Business Overview
6.16.3 Abcepta CD30 (TNFRSF8) Antibody Sales, Revenue and Gross Margin (2018-2025)
6.16.4 Abcepta CD30 (TNFRSF8) Antibody Product Portfolio
6.16.5 Abcepta Recent Developments/Updates
6.17 ProSci Incorporated
6.17.1 ProSci Incorporated Corporation Information
6.17.2 ProSci Incorporated CD30 (TNFRSF8) Antibody Description and Business Overview
6.17.3 ProSci Incorporated CD30 (TNFRSF8) Antibody Sales, Revenue and Gross Margin (2018-2025)
6.17.4 ProSci Incorporated CD30 (TNFRSF8) Antibody Product Portfolio
6.17.5 ProSci Incorporated Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 CD30 (TNFRSF8) Antibody Industry Chain Analysis
7.2 CD30 (TNFRSF8) Antibody Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 CD30 (TNFRSF8) Antibody Production Mode & Process
7.4 CD30 (TNFRSF8) Antibody Sales and Marketing
7.4.1 CD30 (TNFRSF8) Antibody Sales Channels
7.4.2 CD30 (TNFRSF8) Antibody Distributors
7.5 CD30 (TNFRSF8) Antibody Customers
8 CD30 (TNFRSF8) Antibody Market Dynamics
8.1 CD30 (TNFRSF8) Antibody Industry Trends
8.2 CD30 (TNFRSF8) Antibody Market Drivers
8.3 CD30 (TNFRSF8) Antibody Market Challenges
8.4 CD30 (TNFRSF8) Antibody Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Download FREE Sample Report
